Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.34 |
| ▸ | CALML3 | P27482 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Posizolid SCHEMBL7079325 | 1.00 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| Posizolid SCHEMBL14286008 | 1.00 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| Posizolid SCHEMBL374786 | 1.00 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| SCHEMBL7081128 | 0.94 | MAOA (0.34) | MAOACALML3GRM2MAOBF10 | |
| SCHEMBL7081127 | 0.94 | MAOA (0.34) | MAOACALML3GRM2MAOBF10 | |
| SCHEMBL19486038 | 0.93 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19MAOB | |
| SCHEMBL7079423 | 0.93 | CALML3 (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| SCHEMBL7077028 | 0.92 | MAOA (0.32) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| SCHEMBL12673656 | 0.92 | GRM2 (0.34) | MAOAGRM2MAOBF10 | |
| SCHEMBL7077025 | 0.92 | MAOA (0.32) | MAOACALML3GRM2MAOBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795601-B2 | Compositions and methods for cancer treatment | BIOVISTA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795601-B2 | Compositions and methods for cancer treatment | BIOVISTA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012082992-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-7759351-B2 | Oxazolidinone compounds, and compositions and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-20 | — | — | US | disclosed |
| EP-1902050-B1 | OXAZOLIDINONE DERIVATIVES AND USE THEREOF AS ANTIBIOTICS | FERRER INT (ES) | 2009-09-09 | — | — | EP | disclosed |
| US-20090062266-A1 | OXAZOLIDINONE COMPOUNDS, AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2009-03-05 | — | — | US | disclosed |
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | FERRER INTERNACIONAL S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| EP-1786805-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
| EP-1745784-A1 | Oxazolidinone derivatives and use thereof as antibiotics | FERRER INTERNACIONAL, S.A. (ES) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006010756-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S. A. (ES) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062266-A1 | OXAZOLIDINONE COMPOUNDS, AND COMPOSITIONS AND METHODS RELATED THERETO | MAOA, MAOB, AOC2 | MAOA 1/4885CALML3 2764/4885CYP2C9 6/4885 |
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BRAF, ERBB3, ERBB2 | MAOA 554/4885CALML3 2097/4885CYP2C9 2080/4885 |
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | OXA1L, MAOA, NR0B1 | MAOA 2/4885CALML3 3351/4885CYP2C9 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.